We have provided a gene expression–based biomarker to assist with defining the activity of the cGAS-STING pathway, available to the community as a ready to use R script but further work must be performed to validate the different classes of immune activation relative to immunotherapy response across multiple cancer types. This evidence concerns the gene STING1 and cancer.